NEW YORK – Telesis Bio said on Wednesday that it has inked a partnership with Beckman Coulter Life Sciences to establish "efficient and scalable" biofoundries for DNA synthesis.
Financial details of the deal were not disclosed.
Under the partnership, the companies will integrate the Gibson short oligonucleotide ligation assembly (SOLA) enzymatic synthesis technology from Telesis Bio (formerly known as Codex DNA) with the Biomek Echo One automation platform from Beckman Coulter to achieve rapid synthesis of DNA.
"Drawing parallels to the automotive industry’s success with distributed manufacturing, we aim to establish local and on-premise DNA foundries that function as digital-to-biologic converters delivering DNA or mRNA as fast as overnight," Telesis Bio Cofounder and Chief Technology Officer Dan Gibson said in a statement.
"By integrating Gibson SOLA's high-fidelity, scalable, and nontoxic DNA synthesis capabilities with Beckman Coulter Life Sciences automation expertise, we are setting a new standard for on-premises biofoundries," Telesis Bio CEO Eric Esser added.